ADAM LOOSE: Open Payments
NPI 1295216091 · LEXINGTON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$8,155 in 92 payments from 11 companies in 2025. Trend: 2023 $12,887 · 2024 $16,040 · 2025 $8,155
Consulting: $4,857Food & beverage: $1,742Travel & lodging: $1,444Education: $111
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 29 | $6,925 |
| Alkermes, Inc. | 14 | $429 |
| Otsuka America Pharmaceutical, Inc. | 12 | $198 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $197 |
| Teva Pharmaceuticals USA, Inc. | 4 | $154 |
| Lundbeck LLC | 4 | $88 |
| Janssen Pharmaceuticals, Inc | 3 | $66 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $27 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
Products named: COBENFY, ARISTADA, CAPLYTA, ABILIFY ASIMTUFII, ABILIFY MAINTENA, REXULTI, INVEGA SUSTENNA, UZEDY.
Industry payments across KY — which companies pay providers there.
